HRMY vs PRAX
HRMY: Harmony Biosciences is a neuroscience-focused biopharmaceutical company commercializing WAKIX (pitolisant), the first-in-class non-controlled H3 receptor antagonist for narcolepsy, with an expanding pipeline in rare epilepsy and sleep disorders. PRAX: Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing precision therapies for central nervous system disorders driven by neuronal imbalance.
Side-by-side fundamentals
| Metric | HRMY | PRAX | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $38.41 | $360.76 | |
| Market cap as of 2026-08-10 | $2.2B | $10.1B | |
| P/E as of 2026-08-10 | 12.34 | n/a | |
| PEG as of 2026-08-10 | n/a | -5.38 | |
| Net margin as of 2026-08-10 | +18.9% | -2137.5% | HRMY higher |
| Gross margin as of 2026-08-10 | +75.4% | n/a | |
| Operating margin as of 2026-08-10 | +24.0% | -2340.3% | HRMY higher |
| ROE as of 2026-08-10 | +20.1% | -43.0% | HRMY higher |
| ROA as of 2026-08-10 | +14.1% | -40.2% | HRMY higher |
| Debt / equity as of 2026-08-10 | 0.15 | 0.00 | PRAX lower |
| Revenue growth (YoY) as of 2026-08-10 | +24.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +25.6% | n/a | |
| Beta as of 2026-08-10 | 1.02 | 2.82 | |
| 1-year return as of 2026-08-07 close | +12.3% | +663.2% | PRAX higher |
Fundamentals: market data, as of 2026-08-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.